Coherus BioSciences Inc (NAS:CHRS)
$ 1.88 -0.03 (-1.57%) Market Cap: 215.68 Mil Enterprise Value: 440.51 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at UBS BioPharma Conference Transcript

Nov 09, 2023 / 04:30PM GMT
Release Date Price: $1.6 (-21.18%)
Ashwani Verma
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst

Okay. Good day everybody. My name is Ash Verma. I'm a SMID cap biotech and spec pharma analyst at UBS. And with me today is the Coherus team. With us, Denny Lanfear, who's the CEO; Paul Reider, Chief Commercial Officer; and Theresa Lavallee, who is the Chief Development Officer. Thanks for joining us.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Thank you very much for the invitation to the conference, and we're happy to talk to you today, Ash.

Ashwani Verma;Dennis M. Lanfear
UBS Investment Bank, Research Division - Director of Americas Equity Research & US Specialty Pharma Analyst;Coherus BioSciences, Inc. - Chairman, President &

Great. So just maybe start off like with a quick, very brief outline for the company for people that might not be familiar, just like take a couple of quick minutes and then to the questions.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot